Featured Post from ChristianaCare

ChristianaCare Provides More Than $1 Million in Grants to 19 Community Organizations to Address Social Drivers of Health

Dec 1, 2023

3 min

Bettina Tweardy Riveros, J.D.

(WILMINGTON, Del. – December 1, 2023) ChristianaCare is investing $1 million in local nonprofit organizations to improve health for communities in Delaware, Pennsylvania and Maryland.



Announced during a special event Thursday at Ezion Fair Baptist Church in Wilmington’s Southbridge neighborhood, the funding was given to 19 nonprofits through ChristianaCare’s Community Investment Fund. The fund supports partnerships to build the collective capacity of communities to address social, behavioral and environmental factors that impact health.


“In order to improve health equity and accelerate progress in addressing the social drivers of health, we need partners,” said Bettina Tweardy Riveros, chief public affairs officer and chief health equity officer at ChristianaCare. “While ChristianaCare provides excellent health care, we also understand that we are not the experts on every social driver of health. And that’s why we are committed to strengthening these organizations and enhancing their ability to make a positive impact. Together, we are creating health in the neighborhoods and communities we serve.”



As an anchor institution in the community, ChristianaCare invests in community health improvement programs as a core component of its community benefit activities. To date, ChristianaCare has provided more than $4 million to 52 community organizations through its Community Investment Fund, which was established in 2019.


This year’s awardees received funding to support community health improvement initiatives in high-need communities to address a diverse array of health-related needs, including safe housing, access to nutritious food – and even climate change, which the White House recently highlighted as a social driver of health.


One of the organizations that received a grant is Delaware Humanities, which provides educational and cultural opportunities to help Delawareans gain a deeper understanding of human identity. The Wilmington, Del.-headquartered nonprofit will use its grant to develop environmental justice toolkits designed to inspire, facilitate and guide conversations about the importance of environmental issues in Delaware.


“Major focus areas at our organization include health and environment, which impact human behavior and our collective sense of well-being,” said Michele Anstine, executive director of Delaware Humanities. “ChristianaCare’s grant will help us empower our communities so they can more truly understand the deep connection between health and their environment and its profound impact on the human experience.”



Good Neighbors Home Repair, headquartered in Kennett Square, Pennsylvania, received a grant to expand its free home repair services to houses for low-income households, making their homes safer, healthier and more livable.

“Many of the houses that we repair belong to people who are coming home after a hospital discharge,” said Brad Dunn, advancement director for Good Neighbors Home Repair. “They often are returning to homes with broken handrails and misshapen steps but are unable to pay for repairs because they live on fixed incomes. We are deeply appreciative that ChristianaCare is supporting our efforts to provide services that keep our clients safe, healthy and at home.”


Recipients were selected based on the quality of their proposals and implementation plans, and on the alignment of their proposals with the key priorities of ChristianaCare’s Community Health Needs Assessment and Community Health Implementation Plan. The funded initiatives will be implemented throughout the upcoming year.


The 19 latest Community Investment Fund recipients are:

  • AIDS Delaware.
  • Bayside Community Network, Inc.
  • Children & Families First.
  • Cornerstone West CDC.
  • Deep Roots, Inc.
  • Delaware 211.
  • Delaware Center for Justice.
  • Delaware Coalition Against Domestic Violence.
  • Delaware Humanities.
  • Delaware Interfaith Power & Light.
  • Good Neighbors Home Repair.
  • Green Beret Project.
  • Healthy Food for Healthy Kids.
  • Project New Start.
  • Saint Patrick'’s Center.
  • Sussex County Habitat for Humanity.
  • The Resurrection Center.
  • YMCA of Delaware.
  • YWCA Delaware.


Connect with:
Bettina Tweardy Riveros, J.D.

Bettina Tweardy Riveros, J.D.

Chief Public Affairs Officer and Chief Health Equity Officer

Leads health equity and government affairs strategies to advance ChristianaCare's vision and mission to serve the community.

Community EngagementHealth PolicyStrategyVisionGovernment Affairs
Powered by

You might also like...

Check out some other posts from ChristianaCare

3 min

New Study Finds Most Patients Can Safely Continue Weight Loss and Diabetes Drugs Before Gynecologic Surgery

Most patients taking popular weight loss and diabetes medications such as Ozempic and Wegovy can safely continue them before gynecologic surgery, according to a new journal article from ChristianaCare published in Obstetrics & Gynecology. The review found that serious anesthesia risks linked to these drugs are uncommon for most patients and can usually be managed through individualized planning rather than stopping the medication. The paper is the first to take a focused look at glucagon-like peptide-1 receptor agonists, commonly called GLP-1 drugs, in gynecologic surgery. These medications were first approved to treat diabetes and are now widely used to support weight loss and metabolic health, which refers to how the body processes sugar and energy. “Our study shows that the evidence does not support routinely stopping these medications before surgery and that the actual risk is low for most patients,” said Michelle Pacis, M.D., MPH, senior author of the study and a minimally invasive gynecologic surgeon at ChristianaCare. Why these medications raised concerns GLP-1 drugs work in part by slowing how quickly the stomach empties. This helps patients feel full longer, but it also raises concerns for surgery. Doctors worry that food remaining in the stomach could increase the risk of aspiration, when stomach contents enter the lungs during anesthesia. Because of this, early recommendations often advised stopping GLP-1 medications before surgery. The ChristianaCare review found that this approach was largely based on caution rather than strong evidence. The authors reviewed data from multiple studies, including large patient groups, that examined outcomes in people taking GLP-1 drugs during procedures. While some studies showed higher amounts of stomach contents, aspiration events were rare and occurred at rates similar to patients who were not taking the medications. New guidance reflects a change in thinking Recent national guidance from several medical societies now recommends a more tailored approach. Most patients can continue GLP-1 medications before surgery. For patients with higher risk factors, such as significant stomach symptoms or known delayed digestion, simple precautions can reduce risk. These precautions may include a clear liquid diet for 24 hours before surgery or closer monitoring during anesthesia. A clear liquid diet includes fluids like water, broth and clear juices. “This shift recognizes both the benefits of these medications and the importance of patient-specific decision making,” Pacis said. Why this matters for gynecologic surgery Many gynecologic surgeries require patients to be positioned in ways that can affect breathing and circulation. At the same time, many patients needing these procedures also have obesity or diabetes, which can increase surgical risk. GLP-1 medications can improve blood sugar control and support weight loss, helping patients enter surgery in better overall health and enhance recovery. Stopping these drugs without a clear reason may work against those benefits. Practical steps to support patient safety The study outlines several strategies care teams can use when patients remain on GLP-1 medications. These include thoughtful anesthesia planning, careful monitoring of heart and lung function, and, in select cases, the use of ultrasound to check stomach contents before surgery. “The goal is not to ignore risk, but to manage it wisely,” Pacis said. “For many patients, continuing these medications supports safer surgery and better recovery.” The authors note that more research is needed, particularly studies focused specifically on gynecologic surgery. Still, the findings offer clarity for patients and clinicians navigating a rapidly changing area of care. “This review helps bring evidence and balance to an issue that has caused a lot of confusion,” Pacis said. “It supports keeping patients on therapies that benefit their health whenever it is safe to do so.”

1 min

Two Research Scientists at the Cawley Center for Translational Cancer Research Earn Top Honors at UD Biology Research Day

Two rising cancer researchers from ChristianaCare’s Cawley Center for Translational Cancer Research were recognized for outstanding scientific contributions at the University of Delaware’s Annual Biology Research Day Conference on January 30, 2026. The awards highlight the strength and impact of colorectal cancer research underway at the Cawley Center. Anh Nguyen, a third year Ph.D. student, received the conference’s first place poster award for his project, “FGF19/FGFR4 Axis: A Key Driver in Tumor Growth and Treatment Resistance in Colorectal Cancer.” His research explores a signaling pathway that may lead to new strategies for targeting treatment resistant disease. Molly Lausten, a fifth year Ph.D. student, earned third place for her presentation, “Investigating the role of miR 27a 3p in the WNT signaling pathway and chemoresistance in colorectal cancer stem cells.” Her work examines a key microRNA that may influence resistance to therapy, a major challenge in treating aggressive tumors. “These awards reflect far more than individual excellence,” said Bruce M. Boman, M.D., Ph.D., MSPH, FACP, senior scientist and director of Cancer Genetics at the Cawley Center. “They show the power of rigorous, curiosity driven science to move the field forward. Molly and Anh are tackling some of the hardest questions in colorectal cancer, and their success speaks to the innovative environment we are building at ChristianaCare. I could not be more proud of their achievement and their commitment to improving outcomes for patients.”

3 min

Gene Editing Breakthrough Offers New Hope for Head and Neck Cancer Patients

Researchers at the ChristianaCare Gene Editing Institute have made an important advance in treating head and neck cancers. By using CRISPR gene editing, the team found a way to restore how well chemotherapy works in tumors that have stopped responding to treatment. Their results, now published in Molecular Therapy Oncology, could change how doctors treat these aggressive cancers and give new hope to many patients who face limited options. Head and neck cancer is the seventh most common cancer worldwide, and cases are expected to rise by 30 percent every year by 2030. Even with progress in surgery, chemotherapy and immunotherapy, many patients still reach a point where treatment no longer works. The ChristianaCare team aimed to solve this challenge at its source. Targeting the Heart of Drug Resistance The researchers focused on a gene called NRF2. This gene acts like a master switch that helps cancer cells survive stress and resist chemotherapy. Because NRF2 plays such a central role in tumor growth, the team chose to develop a genetic therapy that disables the gene itself rather than targeting a single protein, which is common in traditional drug development. Since NRF2 is a transcription factor, shutting it down in a lasting way is more likely to succeed through CRISPR gene editing. Their major advance was showing that CRISPR can successfully disrupt NRF2 in head and neck cancer cells and in esophageal cancer cells. This work builds on earlier studies in lung cancer, where blocking NRF2 made tumors more sensitive to chemotherapy and improved survival in animal models. “Our goal was to break through the wall of drug resistance that so many patients face,” said Natalia Rivera Torres, Ph.D., the study’s lead author. “By precisely editing the NRF2 gene, we can make cancer cells vulnerable again to standard treatments. This could improve outcomes and quality of life.” Precision Matters: The Power of Target Choice The study also showed that the location of the CRISPR cut within the NRF2 gene makes a big difference. The strongest results came from targeting exon 4, a part of the gene that controls a key section of the NRF2 protein. Editing this region reduced NRF2 levels by 90 percent and made cancer cells much more sensitive to chemotherapy. In comparison, editing exon 2 was less effective even though it still caused high levels of gene disruption. The team also found that a process called exon skipping, where sections of genetic code are rearranged, can affect the outcome of gene editing. This discovery highlights how important careful design and testing are when building gene editing therapies. A Platform for Broader Impact ChristianaCare researchers saw the same results in both head and neck cancer cells and esophageal cancer cells. This suggests the strategy could help treat many solid tumors that have high levels of NRF2 and are known for strong drug resistance. “This is more than just a single experiment,” said Eric Kmiec, Ph.D., director of the Gene Editing Institute and senior author of the study. “We are building a platform that can be adapted to different cancers. Our earlier work in lung cancer showed the promise of this approach, and now we see it working in other hard to treat tumors. It is an exciting step toward making gene editing a meaningful part of cancer treatment.” Looking Ahead: Toward Clinical Application With these strong results, the team is now focused on finding the safest and most effective way to deliver the gene editing tools directly to tumors. Their goal is to reduce how much standard treatment a patient needs in order to get the best result with fewer side effects. “Drug resistance is one of the biggest challenges in cancer care,” Rivera Torres said. “If we can overcome it with gene editing, we could give patients more time, better quality of life and a renewed sense of hope.” Kmiec added, “We are committed to moving this technology forward quickly while always keeping the patient in mind. The future of cancer treatment is personal, precise and, we believe, within reach.”

View all posts
Powered by